ClinicalTrials.gg
CompletedNCT01973569DESIRABLEUpdated Feb 12, 2020Results posted

AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment

An interventional study of denosumab and placebo in Rheumatoid Arthritis, sponsored by Daiichi Sankyo. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-02-12.

Sponsored by Daiichi Sankyo · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
679
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 153 studies in Arthritis, Rheumatoid with a site in Japan — 9 open to participants now, 12 under way, 2 of them phase 3. Arthritis, Rheumatoid · Japan.

Enrollment
21st of 132
679 · median 265
Started
2013
with 8 others
No phase
Only one
of the 153
Registered
84th of 153
by date

Among the 153 studies in Arthritis, Rheumatoid with a site in Japan, this one is the 21st largest by enrollment of the 132 interventional ones that give a count, is one of 9 that started in 2013, is the only one with no phase, and was the 84th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

9 of the 153 studies in Arthritis, Rheumatoid with a site in Japan are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Arthritis, Rheumatoid with a site in Japan, or all of them as a file.
02

Study summary

To evaluate the inhibitory effect of progression, compared with placebo, in joint destruction by AMG 162 administered subcutaneously to rheumatoid arthritis participants.

Read the detailed description

To evaluate the inhibitory effect of progression, compared with placebo, in joint destruction by AMG 162 administered subcutaneously at a dose of 60 mg every 6 months or every 3 months for 12 months to rheumatoid arthritis participants.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • Denosumab
  • RANKL
  • RANK
  • AMG 162
  • joint damage
  • Developmental Phase III
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with rheumatoid arthritis according to the American College of Rheumatology (ACR) criteria for rheumatoid arthritis classification (1987 revision) or the 2010 ACR-EULAR (The European League Against Rheumatism) classification criteria for rheumatoid arthritis

Exclusion criteria

Exclusion Criteria:

  • Functional class IV according by the ACR revised classification (1991)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
679 participants (actual)

Study arms

  • Experimental
    Denosumab 6 months

    denosumab administered subcutaneously every 6 months

    Drug: denosumab

  • Experimental
    Denosumab 3 months

    denosumab administered subcutaneously every 3 months

    Drug: denosumab

  • Placebo comparator
    placebo

    placebo administered subcutaneously to match denosumab

    Drug: placebo

Interventions

  • denosumab administered subcutaneously

    Also known as: AMG 162

  • Drugplacebo

    placebo administered subcutaneously to match denosumab

06

What researchers measure

Primary outcomes

  1. Change in Total Sharp Score (TSS) From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo

    Change from baseline in Total Sharp Score (TSS) from baseline to month 12 was assessed. The TSS was defined as the sum of the erosion score and the joint space narrowing scores from radiographic assessments. The maximum radiographic TSS from the both hands/wrists and both feet is 448. Higher values represented greater damage.

    Time frame: baseline to month 12

Secondary outcomes

  1. Change in Total Sharp Score (TSS) From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo

    Change from baseline in Total Sharp Score (TSS) from baseline to month 6 was assessed. The TSS was defined as the sum of the erosion score and the joint space narrowing scores from radiographic assessments. The maximum radiographic TSS from the both hands/wrists and both feet is 448. Higher values represented greater damage.

    Time frame: baseline to month 6

  2. Change in Erosion Score From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo

    Change from baseline in Erosion Score from baseline to month 6 was assessed. The Erosion Score was defined for the sum of the joint level erosion scores among the 44 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Erosion Score from both hands/wrist and both feet is 280. Higher values represented greater damage.

    Time frame: baseline to month 6

  3. Change in Joint Space Narrowing From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo

    Change from baseline in Joint Space Narrowing from baseline to month 6 was assessed. Joint Space Narrowing was defined for the sum of the joint level joint space narrowing scores among the 42 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Joint Space Narrowing from both hands/wrists and both feet is 168. Higher values represented greater damage.

    Time frame: baseline to month 6

  4. Change in Erosion Score From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo

    Change from baseline in Erosion Score from baseline to month 12 was assessed. The Erosion Score was defined for the sum of the joint level erosion scores among the 44 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Erosion Score from both hands/wrist and both feet is 280. Higher values represented greater damage.

    Time frame: baseline to month 12

  5. Change in Joint Space Narrowing From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo

    Change from baseline in Joint Space Narrowing from baseline to month 12 was assessed. Joint Space Narrowing was defined for the sum of the joint level joint space narrowing scores among the 42 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Joint Space Narrowing from both hands/wrists and both feet is 168. Higher values represented greater damage.

    Time frame: baseline to month 12

  6. Percent Change in Bone Mineral Density (BMD) From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo

    The percent change from baseline in Bone Mineral Density (BMD) to month 12 was assessed. Bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA).

    Time frame: baseline to month 12

07

Results

Posted Dec 13, 2019

Participant flow

A total of 679 participants who met all inclusion and none of the exclusion criteria were included in the study; efficacy outcomes were assessed in the Full Analysis Set (n=654).

Participant flow — Overall Study
MilestoneDenosumab 6 MonthsDenosumab 3 MonthsPlacebo
Started228225226
Received study drug222222223
Did not receive study drug633
Discontinued study treatment232215
Discontinued study232215
Completed199200208
Not completed292518
Withdrew: Adverse event924
Withdrew: Protocol violation213
Withdrew: Withdrawal by subject752
Withdrew: Invasive dental treatment356
Withdrew: Prohibited concomitant d150
Withdrew: Disease progression030
Withdrew: Other110
Withdrew: Did not receive study drug633

Outcome measures

PrimaryChange in Total Sharp Score (TSS) From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo

Change from baseline in Total Sharp Score (TSS) from baseline to month 12 was assessed. The TSS was defined as the sum of the erosion score and the joint space narrowing scores from radiographic assessments. The maximum radiographic TSS from the both hands/wrists and both feet is 448. Higher values represented greater damage.

Time frame:
baseline to month 12
Reported as:
Mean · score on a scale
Change in Total Sharp Score (TSS) From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo
score on a scaleDenosumab 6 MonthsDenosumab 3 MonthsPlacebo
Change in Total Sharp Score (TSS) From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo0.99 (0.49 to 1.49)0.72 (0.41 to 1.03)1.49 (0.99 to 1.99)
Statistical analysis
  • Denosumab 6 Months vs Placebo · van Elteren stratified rank test · p = 0.0235 (The hierarchical testing procedure was applied for multiple comparisons of the primary endpoint. First, comparison between AMG 162 60mg Q3M vs placebo is tested. Only if it is rejected, comparison of AMG 162 60mg Q6M vs placebo is formally tested.)van Elteren stratified rank test adjusting for baseline use of glucocorticoid was used.
SecondaryChange in Total Sharp Score (TSS) From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo

Change from baseline in Total Sharp Score (TSS) from baseline to month 6 was assessed. The TSS was defined as the sum of the erosion score and the joint space narrowing scores from radiographic assessments. The maximum radiographic TSS from the both hands/wrists and both feet is 448. Higher values represented greater damage.

Time frame:
baseline to month 6
Reported as:
Mean · score on a scale
Change in Total Sharp Score (TSS) From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo
score on a scaleDenosumab 6 MonthsDenosumab 3 MonthsPlacebo
Change in Total Sharp Score (TSS) From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo0.62 (0.27 to 0.98)0.48 (0.24 to 0.72)0.92 (0.60 to 1.23)
Statistical analysis
  • Denosumab 6 Months vs Placebo · van Elteren stratified rank test · p = 0.0360van Elteren stratified rank test adjusting for baseline use of glucocorticoid was used.
SecondaryChange in Erosion Score From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo

Change from baseline in Erosion Score from baseline to month 6 was assessed. The Erosion Score was defined for the sum of the joint level erosion scores among the 44 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Erosion Score from both hands/wrist and both feet is 280. Higher values represented greater damage.

Time frame:
baseline to month 6
Reported as:
Mean · score on a scale
Change in Erosion Score From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo
score on a scaleDenosumab 6 MonthsDenosumab 3 MonthsPlacebo
Change in Erosion Score From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo0.34 (0.16 to 0.53)0.13 (0.03 to 0.24)0.58 (0.39 to 0.78)
Statistical analysis
  • Denosumab 6 Months vs Placebo · van Elteren stratified rank test · p = 0.1323van Elteren stratified rank test adjusting for baseline use of glucocorticoid was used.
SecondaryChange in Joint Space Narrowing From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo

Change from baseline in Joint Space Narrowing from baseline to month 6 was assessed. Joint Space Narrowing was defined for the sum of the joint level joint space narrowing scores among the 42 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Joint Space Narrowing from both hands/wrists and both feet is 168. Higher values represented greater damage.

Time frame:
baseline to month 6
Reported as:
Mean · score on a scale
Change in Joint Space Narrowing From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo
score on a scaleDenosumab 6 MonthsDenosumab 3 MonthsPlacebo
Change in Joint Space Narrowing From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo0.28 (0.07 to 0.50)0.35 (0.17 to 0.53)0.33 (0.18 to 0.48)
Statistical analysis
  • Denosumab 6 Months vs Placebo · van Elteren stratified rank test · p = 0.0448van Elteren stratified rank test adjusting for baseline use of glucocorticoid was used.
SecondaryChange in Erosion Score From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo

Change from baseline in Erosion Score from baseline to month 12 was assessed. The Erosion Score was defined for the sum of the joint level erosion scores among the 44 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Erosion Score from both hands/wrist and both feet is 280. Higher values represented greater damage.

Time frame:
baseline to month 12
Reported as:
Mean · score on a scale
Change in Erosion Score From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo
score on a scaleDenosumab 6 MonthsDenosumab 3 MonthsPlacebo
Change in Erosion Score From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo0.51 (0.22 to 0.80)0.22 (0.09 to 0.34)0.98 (0.65 to 1.31)
Statistical analysis
  • Denosumab 6 Months vs Placebo · van Elteren stratified rank test · p = 0.0104van Elteren stratified rank test adjusting for baseline use of glucocorticoid was used.
SecondaryChange in Joint Space Narrowing From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo

Change from baseline in Joint Space Narrowing from baseline to month 12 was assessed. Joint Space Narrowing was defined for the sum of the joint level joint space narrowing scores among the 42 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Joint Space Narrowing from both hands/wrists and both feet is 168. Higher values represented greater damage.

Time frame:
baseline to month 12
Reported as:
Mean · score on a scale
Change in Joint Space Narrowing From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo
score on a scaleDenosumab 6 MonthsDenosumab 3 MonthsPlacebo
Change in Joint Space Narrowing From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo0.48 (0.20 to 0.76)0.50 (0.27 to 0.74)0.51 (0.28 to 0.74)
Statistical analysis
  • Denosumab 6 Months vs Placebo · van Elteren stratified rank test · p = 0.2570van Elteren stratified rank test adjusting for baseline use of glucocorticoid was used.
SecondaryPercent Change in Bone Mineral Density (BMD) From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo

The percent change from baseline in Bone Mineral Density (BMD) to month 12 was assessed. Bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA).

Time frame:
baseline to month 12
Reported as:
Mean · percent change
Percent Change in Bone Mineral Density (BMD) From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo
percent changeDenosumab 6 MonthsDenosumab 3 MonthsPlacebo
Percent Change in Bone Mineral Density (BMD) From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo3.99 ± 0.244.88 ± 0.24-1.03 ± 0.25
Statistical analysis
  • Denosumab 6 Months vs Placebo · Regression, Cox · p = <0.0001 · Mean difference (net): 5.02 · 95% CI 4.41 to 5.63ANCOVA model adjusting for treatment, baseline (BL) value, machine type, BL value-by-machine type interaction, and BL use of glucocorticoid was used.

Adverse events

Collected over Adverse event data were collected from the first dose to the last dose of study drug, up to 12 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab 6 Months0/221 (0%)19/221 (8.6%)127/221 (57.5%)
Denosumab 3 Months1/222 (0.5%)19/222 (8.6%)122/222 (55%)
Placebo0/224 (0%)13/224 (5.8%)125/224 (55.8%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventDenosumab 6 MonthsDenosumab 3 MonthsPlacebo
Benign prostatic hyperplasiaReproductive system and breast disorders2/2210/2220/224
Immune thrombocytopenic purpuraBlood and lymphatic system disorders1/2210/2220/224
EnterocolitisGastrointestinal disorders1/2210/2220/224
Abscess jawInfections and infestations1/2210/2220/224
Pyelonephritis acuteInfections and infestations1/2210/2220/224
SepsisInfections and infestations1/2210/2220/224
TuberculosisInfections and infestations1/2210/2220/224
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/2210/2220/224
SpondylolisthesisMusculoskeletal and connective tissue disorders1/2210/2220/224
SynovitisMusculoskeletal and connective tissue disorders1/2210/2220/224
Most frequent other events
Most frequent other events
EventDenosumab 6 MonthsDenosumab 3 MonthsPlacebo
NasopharyngitisInfections and infestations79/22169/22273/224
StomatitisGastrointestinal disorders22/22127/22213/224
Hepatic function abnormalHepatobiliary disorders14/22113/22220/224
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders18/2218/2229/224
PharyngitisInfections and infestations13/22116/22216/224
Dental cariesGastrointestinal disorders12/2217/2229/224
Back painMusculoskeletal and connective tissue disorders5/22112/2227/224
InfluenzaInfections and infestations8/22110/22212/224

Baseline characteristics

The Baseline Analysis Population included participants in the Full Analysis Set (FAS). The FAS was defined as all randomized participants excluding those who met any of the following criteria: * Received no investigational product * Had no baseline TSS or no available TSS after the first administration of the investigational product

Age, Categorical
Age, Categorical(Participants)Denosumab 6 MonthsDenosumab 3 MonthsPlaceboTotal
<=18 years0000
Between 18 and 65 years140150163453
>=65 years776955201
Age, Continuous
Age, Continuous(years)Denosumab 6 MonthsDenosumab 3 MonthsPlaceboTotal
Mean58.1 ± 12.358.2 ± 12.0455.8 ± 11.757.4 ± 12.04
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab 6 MonthsDenosumab 3 MonthsPlaceboTotal
Female168154167489
Male496551165
Region of Enrollment
Region of Enrollment(participants)Denosumab 6 MonthsDenosumab 3 MonthsPlaceboTotal
Japan217219218654
Body mass index (BMI)
Body mass index (BMI)(kg/m^2)Denosumab 6 MonthsDenosumab 3 MonthsPlaceboTotal
Mean22.38 ± 3.6822.64 ± 3.6222.65 ± 3.4922.56 ± 3.59
08

Study locations

1 site
  • Tokyo, 162-0054, Japan
09

References and documents

Publications

  • Tanaka Y, Takeuchi T, Soen S, Yamanaka H, Yoneda T, Tanaka S, Nitta T, Okubo N, Genant HK, van der Heijde D. Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study. J Rheumatol. 2021 Nov;48(11):1663-1671. doi: 10.3899/jrheum.201376. Epub 2021 Apr 15. PubMed 33858976 ↗
  • Takeuchi T, Soen S, Ishiguro N, Yamanaka H, Tanaka S, Kobayashi M, Okubo N, Nitta T, Tanaka Y. Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. Mod Rheumatol. 2021 Jan;31(1):34-41. doi: 10.1080/14397595.2019.1703484. Epub 2020 Jan 9. PubMed 31826682 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https:// vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Dec 2015, 26 months.

Results were first posted in Dec 2019, 4 years after primary completion.

Of 56 industry-sponsored interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 92. This study's 26 months is below that.

Counting every sponsor, half of 348 studies reached it within 27 months; a quarter within 13 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2013
First posted
Oct 31, 2013
StartActual
Oct 2013
Primary completionActual
Dec 2015
CompletionActual
Sep 19, 2017
Results first posted
Dec 13, 2019
Last update
Feb 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01973569
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Oct 31, 2013
Start date
Oct 2013
Primary completion
Dec 2015
Completion
Sep 19, 2017
Results posted
Dec 13, 2019
Last update
Feb 12, 2020

Study contacts

Tsutomu Takeuchi, Prof.
study director · Division of Rheumatology Department of Internal Medicine, Keio University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion